Ischemic Stroke Clinical Trial
— HIBISCUSSTROKEOfficial title:
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke.
NCT number | NCT03149705 |
Other study ID # | 69HCL17_0323 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | October 13, 2016 |
Est. completion date | October 2026 |
Ischemic stroke is the first cause of acquired disability of the adult, the second cause of
dementia and the third cause of death in the industrialized countries, what constitutes à
major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an
ischemic mechanism (85% of the cases) or hemorrhagic mechanism (15%). For a long time, the
only approved treatment was the intravenous thrombolysis (rt-PA). Recently, thrombectomy has
proven its superiority in this pathology.
Cohorts of patients with stroke are rare but can be very valuable by their clinical,
laboratory and imaging well documented. They are the source of new hypotheses for research or
interventions as well as the quality of care assessment tool.
The main objective of this project is to identify new markers: biological and imaging,
treatment response and prognosis after ischemic stroke.
Secondary objectives of the HIBISCUS-STROKE cohort are to establish a clinical database,
completed by biological samples and by imaging data that can be used in the following areas:
- Descriptive epidemiology of ischemic stroke and cerebral reperfusion,
- Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of
treatment in real life, costs
- Assessment of the long-term effect of the treatment on the occurrence of disability,
stroke recurrence and death,
- Quality of life and personal, familial, professional and social consequences of stroke,
- Research of new diagnostic and prognostic biomarkers,
- Research projects.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | October 2026 |
Est. primary completion date | October 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age> 18 years - Ischemic Stroke confirmed by MRI - Proximal arterial occlusion (ICA or M1) - Eligible for thrombolysis and/or thrombectomy Exclusion Criteria: - Patients residing> 50 km from the Pierre Wertheimer Hospital (Lyon, France) - Inability to perform the first sample (H0) - Patient with progressive or uncontrolled cancer. - Refusal to participate in the study or to sign the consent - Lack of medical social coverage - Deprivation of civil rights |
Country | Name | City | State |
---|---|---|---|
France | Hôpital neurologique Pierre Wertheimer (Lyon) | Bron |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Degree of disability (mRS Score) | Degree of disability: modified Rankin Score | 5 years | |
Secondary | infarct size | cerebral infarct size on MRI | day 6 | |
Secondary | Hemorrhagic transformation | Hemorrhagic transformation (ECASS scale) on imaging (CT or MRI) | 24 hours | |
Secondary | Neurological deficit | Neurological deficit NIH stroke Scale | up to 5 years | |
Secondary | Quality of life | QOL questionnaire | up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT01968122 -
Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China
|
N/A |